Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 15;23(1):e147887.
doi: 10.5812/ijpr-147887. eCollection 2024 Jan-Dec.

The Role of Zinc Supplementation in Alleviating Inflammatory Biomarkers in Patients Undergoing Hemodialysis: A Randomized Placebo Controlled, Crossover Trial

Shayan Mastoor-Tehrani  1 , Fariba Samadian  2 , Hadi Esmaily  1 , Alireza Kargar  1 , Nasim Markazi  2 , Shideh Anvari  3 , Shadi Ziaie  1
Affiliations

The Role of Zinc Supplementation in Alleviating Inflammatory Biomarkers in Patients Undergoing Hemodialysis: A Randomized Placebo Controlled, Crossover Trial

Shayan Mastoor-Tehrani et al. Iran J Pharm Res. .

Abstract

Background: Chronic kidney disease (CKD), which progresses to end-stage renal disease (ESRD) and requires maintenance hemodialysis (MHD), is a global health issue. Inflammation in MHD patients is associated with increased mortality and cardiovascular events. Zinc, essential for immune function and possessing anti-inflammatory properties, is frequently deficient in these patients and could potentially help mitigate inflammation.

Objectives: This study aims to assess the impact of zinc supplementation on inflammatory biomarkers, specifically (CRP) and the neutrophil-to-lymphocyte ratio (NLR), in MHD patients.

Methods: In a double-blind, randomized controlled crossover trial conducted at Labafinejad Hospital, Tehran, MHD patients with zinc deficiency were initially allocated to either a zinc supplementation group or a placebo group. After 30 days, the groups were crossed over, with patients initially receiving zinc now receiving a placebo and vice versa. The primary outcome was changes in serum zinc levels, while secondary outcomes focused on CRP and NLR levels.

Results: Significant changes in serum zinc levels were observed in both groups from baseline to Month 2 (drug-placebo group: Mean change -15.9±10.33 µg/dL, P < 0.05; placebo-drug group: Mean change -14.70 ± 12.58 µg/dL, P < 0.05). A significant initial reduction in CRP levels at Month 1 (P = 0.045) was not sustained at Month 2 (P = 0.812). No statistically significant changes in NLR were noted. Improvements in quality of life, including reductions in muscle pain and skin dryness, were significant in the drug-placebo group (P < 0.05).

Conclusions: Zinc supplementation in MHD patients significantly improved serum zinc levels and initially reduced CRP levels, highlighting its potential role in managing inflammation. Although the impact on NLR was not significant, overall patient outcomes and quality of life showed promising improvements.

Keywords: CRP; MHD; NLR; Quality of Life; Zinc Deficiency.

PubMed Disclaimer

Conflict of interest statement

Shadi Ziaie was the reviewer of this journal, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1.
Figure 1.. Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participant progression through the phases of the randomized crossover trial
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. G. B. D. Chronic Kidney Disease Collaboration Global, Regional, and National Burden of Chronic Kidney Disease, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–33. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765. - DOI - PMC - PubMed
    1. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):A6–7. doi: 10.1053/j.ajkd.2019.09.003. - DOI - PubMed
    1. Cobo G, Lindholm B, Stenvinkel P. Chronic Inflammation in End-Stage Renal Disease and Dialysis. Nephrol Dial Transplant. 2018;33(suppl_3):iii35–40. doi: 10.1093/ndt/gfy175. - DOI - PMC - PubMed
    1. Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM, Perez-Garcia R. Inflammatory Syndrome in Patients on Hemodialysis. J Am Soc Nephrol. 2006;17(12 Suppl 3):S274–80. doi: 10.1681/ASN.2006080926. - DOI - PubMed

LinkOut - more resources